glp 1 drugs and alcohol GLP-1s Hold Promise as Treatment for Use Disorder GLP-1 medications: The next big
Description
doi: 10.1186/s12902-025-01996-z
Funding The authors have no funding for this project to declare
Moreover, in many national health systems, obesity pharmacotherapy is prescribed in specialist obesity services [114]
Supply : In 2025, supply bottlenecks will continue to ease following extensive efforts by Novo Nordisk and Lilly to step up manufacturing, with important implications for competitive dynamics: The large-scale opportunity for compounders will be closing
